TLX vs. TEVA, INSM, SMMT, ITCI, GMAB, RDY, QGEN, VTRS, ASND, and MRNA
Should you be buying Telix Pharmaceuticals stock or one of its competitors? The main competitors of Telix Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.
Telix Pharmaceuticals vs. Its Competitors
Teva Pharmaceutical Industries (NYSE:TEVA) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.
Telix Pharmaceuticals has lower revenue, but higher earnings than Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries currently has a consensus price target of $24.13, suggesting a potential upside of 44.89%. Telix Pharmaceuticals has a consensus price target of $22.33, suggesting a potential upside of 42.34%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, equities analysts clearly believe Teva Pharmaceutical Industries is more favorable than Telix Pharmaceuticals.
In the previous week, Teva Pharmaceutical Industries had 7 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 14 mentions for Teva Pharmaceutical Industries and 7 mentions for Telix Pharmaceuticals. Teva Pharmaceutical Industries' average media sentiment score of 1.08 beat Telix Pharmaceuticals' score of 0.53 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.
54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Telix Pharmaceuticals has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -7.74%. Teva Pharmaceutical Industries' return on equity of 45.44% beat Telix Pharmaceuticals' return on equity.
Summary
Teva Pharmaceutical Industries beats Telix Pharmaceuticals on 11 of the 14 factors compared between the two stocks.
Get Telix Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Telix Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:TLX) was last updated on 7/9/2025 by MarketBeat.com Staff
